Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

1.

A PALB2 mutation associated with high risk of breast cancer.

Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes GB, Winship I, Baglietto L, Giles GG, Goldgar DE, Foulkes WD, Hopper JL; kConFab for the Beast Cancer Family Registry.

Breast Cancer Res. 2010;12(6):R109. doi: 10.1186/bcr2796. Epub 2010 Dec 23.

PMID:
21182766
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia.

Teo ZL, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L, Southey MC.

Fam Cancer. 2013 Dec;12(4):587-95. doi: 10.1007/s10689-013-9620-4.

PMID:
23471749
[PubMed - indexed for MEDLINE]
3.

Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.

Haanpää M, Pylkäs K, Moilanen JS, Winqvist R.

BMC Med Genet. 2013 Aug 13;14:82. doi: 10.1186/1471-2350-14-82.

PMID:
23941127
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Breast-cancer risk in families with mutations in PALB2.

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M.

N Engl J Med. 2014 Aug 7;371(6):497-506. doi: 10.1056/NEJMoa1400382.

PMID:
25099575
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.

Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E, Robidoux A, Martin G, Bismar TA, Tischkowitz M, Rousseau F, Narod SA.

Breast Cancer Res. 2007;9(6):R83.

PMID:
18053174
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Penetrance analysis of the PALB2 c.1592delT founder mutation.

Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL.

Clin Cancer Res. 2008 Jul 15;14(14):4667-71. doi: 10.1158/1078-0432.CCR-08-0210.

PMID:
18628482
[PubMed - indexed for MEDLINE]
Free Article
7.

Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ.

Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741-7.

PMID:
10498392
[PubMed - indexed for MEDLINE]
Free Article
8.

Tumour morphology predicts PALB2 germline mutation status.

Teo ZL, Provenzano E, Dite GS, Park DJ, Apicella C, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L; kConFab, Buys SS, Andrulis IL, Mulligan AM, Glendon G, John EM, Terry MB, Daly M, Odefrey FA, Nguyen-Dumont T, Giles GG, Dowty JG, Winship I, Goldgar DE, Hopper JL, Southey MC.

Br J Cancer. 2013 Jul 9;109(1):154-63. doi: 10.1038/bjc.2013.295. Epub 2013 Jun 20.

PMID:
23787919
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Apr;114(3):457-62. doi: 10.1007/s10549-008-0036-z. Epub 2008 Apr 30.

PMID:
18446436
[PubMed - indexed for MEDLINE]
10.

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.

Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN.

BMC Med Genet. 2013 Jan 9;14:5. doi: 10.1186/1471-2350-14-5.

PMID:
23302520
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.

Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T; kConFab, Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC.

Breast Cancer Res. 2013 Feb 28;15(1):R17. doi: 10.1186/bcr3392.

PMID:
23448497
[PubMed - in process]
Free PMC Article
12.

PALB2 mutations in familial breast and pancreatic cancer.

Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N.

Fam Cancer. 2011 Jun;10(2):225-31. doi: 10.1007/s10689-011-9426-1.

PMID:
21365267
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.

Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD.

Clin Genet. 2009 Nov;76(5):421-6. doi: 10.1111/j.1399-0004.2009.01277.x.

PMID:
19863560
[PubMed - indexed for MEDLINE]
14.

Rare germline mutations in PALB2 and breast cancer risk: a population-based study.

Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallée MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L; WECARE Study Collaborative Group, Bernstein JL, Begg CB.

Hum Mutat. 2012 Apr;33(4):674-80. doi: 10.1002/humu.22022. Epub 2012 Feb 15.

PMID:
22241545
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

PALB2 sequence variants in young South African breast cancer patients.

Sluiter M, Mew S, van Rensburg EJ.

Fam Cancer. 2009;8(4):347-53. doi: 10.1007/s10689-009-9241-0. Epub 2009 Mar 31.

PMID:
19333784
[PubMed - indexed for MEDLINE]
16.

The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.

Heikkinen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Blomqvist C, Nevanlinna H.

Clin Cancer Res. 2009 May 1;15(9):3214-22. doi: 10.1158/1078-0432.CCR-08-3128. Epub 2009 Apr 21.

PMID:
19383810
[PubMed - indexed for MEDLINE]
Free Article
17.

BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.

Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ.

Breast Cancer Res Treat. 2011 Jun;127(3):853-9. doi: 10.1007/s10549-011-1443-0. Epub 2011 Mar 16.

PMID:
21409391
[PubMed - indexed for MEDLINE]
18.

Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.

García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldés T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MI, San Román C, Robles-Díaz L, Urioste M, Benítez J.

Breast Cancer Res Treat. 2009 Feb;113(3):545-51. doi: 10.1007/s10549-008-9945-0. Epub 2008 Feb 27.

PMID:
18302019
[PubMed - indexed for MEDLINE]
19.

A PALB2 germline mutation associated with hereditary breast cancer in Italy.

Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, Palli D.

Fam Cancer. 2010 Jun;9(2):181-5. doi: 10.1007/s10689-009-9295-z. Epub 2009 Sep 18.

PMID:
19763884
[PubMed - indexed for MEDLINE]
20.

Evidence against PALB2 involvement in Icelandic breast cancer susceptibility.

Gunnarsson H, Arason A, Gillanders EM, Agnarsson BA, Johannesdottir G, Johannsson OT, Barkardottir RB.

J Negat Results Biomed. 2008 Jul 17;7:5. doi: 10.1186/1477-5751-7-5.

PMID:
18637200
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk